TEVA-TECNAL C 1/2 CAPSULE

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

BUTALBITAL; CAFFEINE; ACETYLSALICYLIC ACID; CODEINE PHOSPHATE

Mevcut itibaren:

TEVA CANADA LIMITED

ATC kodu:

N02AA79

INN (International Adı):

CODEIN, COMBINATIONS WITH PSYCHOLEPTICS

Doz:

50MG; 40MG; 330MG; 30MG

Farmasötik formu:

CAPSULE

Kompozisyon:

BUTALBITAL 50MG; CAFFEINE 40MG; ACETYLSALICYLIC ACID 330MG; CODEINE PHOSPHATE 30MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100/500

Reçete türü:

Narcotic (CDSA I)

Terapötik alanı:

OPIATE AGONISTS

Ürün özeti:

Active ingredient group (AIG) number: 0401238001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2013-04-15

Ürün özellikleri

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
TEVA-TECNAL C1/4
Butalbital, Acetylsalicylic Acid, Caffeine, and Codeine Phosphate
Capsules
50 mg / 330 mg / 40 mg / 15 mg
USP
N
TEVA-TECNAL C1/2
Butalbital, Acetylsalicylic Acid, Caffeine, and Codeine Phosphate
Capsules
50 mg / 330 mg / 40 mg / 30 mg
USP
COMBINATION ANALGESIC
Teva Canada Limited
Date of Revision:
30 Novopharm Court
November 13, 2018
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Control #: 220040
PAGE 2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
5
ADVERSE REACTIONS
.................................................................................................
14
DRUG INTERACTIONS
..................................................................................................
17
DOSAGE AND ADMINISTRATION
..............................................................................
18
OVERDOSAGE
................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 23
STORAGE AND STABILITY
..........................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 26
PART II: SCIENTIFIC INFORMATION
................................................................................
27
PHARMACEUTICAL INFORMATION
.........................................................................
27